Humanitas Research Hospital
Rozzano, Italy, 20089
Location status: Recruiting
Location contact
Francesco Amati, MD
CONTACT
Lisa Usuelli, MD
CONTACT
NCT Number: NCT07790614
The CT-IPF ANTHEM study is designed to prospectively compare PCDCT to HRCT scan in the identification of specific ILD diagnosis discussed during the multidisciplinary discussion to increase diagnostic confidence and reduce unclassifiable ILD cases.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Rozzano, Italy, 20089
Location status: Recruiting
Francesco Amati, MD
CONTACT
Lisa Usuelli, MD
CONTACT
The advent of a new generation of CT systems based on photon-counting detector technology is raising great interest in the medical community, anticipating a major improvement in numerous clinical applications including chest disorders. These expectations are drawn from the technological advantages inherent to these new CT systems, including a higher contrast-to-noise ratio, higher spatial resolution, and lower radiation dose together with the potential of multienergy imaging.
Non-contrast enhanced CT will be acquired in spectral ultra-high-resolution mode on a clinical dual-source photon-counting detector CT (PCDCT) (NAEOTOM Alpha, Siemens Healthineers AG, Forchheim, Germany). All scans will be acquired with automated exposure control.
Recent evidence showed that images obtained with PCDCT allowed a more precise depiction of CT features of ILDs with similar radiation dose. Subjective visualization of specific IPF features, such as reticulation and traction bronchiectasis, using PCDCT has been rated superior to conventional HRCT. Thus, a more precise delineation of fine fibrotic abnormalities could modify the categorization of ILD patterns and improve the diagnostic confidence of IPF and not-IPF diagnosis, reducing the prevalence of unclassifiable ILD.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Non-contrast enhanced CT will be acquired in spectral ultra-high-resolution mode on a clinical dual-source photon-counting detector CT (PCDCT) (NAEOTOM Alpha, Siemens Healthineers AG, Forchheim, Germany). All scans will be acquired with automated exposure control.
Time frame: 2 years
Time frame: 2 years
Time frame: 2 years
Contact information is provided by the study sponsor or research team.
Francesco Amati, MD
CONTACT
Lisa Usuelli, MD
CONTACT
Istituto Clinico Humanitas
Other
Acronym: CT-IPF ANTHEM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06747923
IPF, Idiopathic Pulmonary Fibrosis
Goyang, South Korea
View Trial DetailsNCT07169253
Alveolitis, Extrinsic Allergic, Fibrotic Lung Disease
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06644144
CTD-ILD, Chronic Hypersensitivity Pneumonitis
Amsterdam, North Holland, Netherlands
View Trial DetailsNCT02503657
Fibrosis, IPF
Hershey, Pennsylvania, United States
View Trial Details